Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Key Inclusion Criteria:

   1. Diagnosis of IPF as defined by American Thoracic Society (ATS)/European Respiratory
   Society (ERS)/Japan Radiological Society (JRS)/Latin American Thoracic Association
   (ALAT) guidelines within the past 7 years prior to study participation.

   2. High-resolution computed tomography (HRCT) scan at screening, with ≥10% to <50%
   parenchymal fibrosis (reticulation) and <25% honeycombing.

   3. FVCpp value >45% and <95% at screening and Day 1 (prior to randomization).

   4. Diffusing capacity of the lungs for carbon monoxide (DLCO) percent predicted and
   corrected by hemoglobin (Hb) value ≥25% and ≤90% at screening (determined locally).

   5. Not currently receiving treatment for IPF with an approved therapy (that is,
   pirfenidone or nintedanib) for any reason, including prior intolerance or lack of
   response to an approved IPF therapy, or choice to forego treatment with an approved
   IPF therapy after a full discussion with the Investigator regarding risks/benefits of
   such therapy.

Key Exclusion Criteria:

   1. Previous exposure to pamrevlumab.

   2. Evidence of significant obstructive lung disease.

   3. Female participants who are pregnant or nursing.

   4. Smoking within 3 months of screening and/or unwilling to avoid smoking throughout the
   study.

   5. Interstitial lung disease other than IPF.

   6. Sustained improvement in the severity of IPF during the 12 months prior to screening.

   7. History of other types of respiratory diseases including diseases or disorders of the
   airways, lung parenchyma, pleural space, mediastinum, diaphragm, or chest wall.

   8. Medical conditions (for example, myocardial infarction [MI]/stroke within the past 6
   month), or logistical challenges that in the opinion of the Investigator preclude the
   participant's adequate participation in the study.

   9. Acute IPF exacerbation during screening or randomization.

10. Use of any investigational drugs or unapproved therapies, or participation in any
   clinical trial with an investigational new drug within 30 days prior to screening. Or
   use of approved IPF therapies (that is, pirfenidone or nintedanib) within 1 week prior
   to screening.

11. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine
   monoclonal antibodies, or to any component of the excipient.